CFRXQ

0.0001--
WG

William Garrett Nichols

Interim Chief Medical Officer

Dr. William Garrett Nichols, MD, MS, serves as Interim Chief Medical Officer at ContraFect Corporation since August 2022. He joined ContraFect Corporation in August 2022. He serves as Chief Medical Officer of Candel Therapeutics, Inc. since September 2022. He served as Chief Medical Officer of Istari Oncology, Inc. Dr. Nichols served as Chief Medical Officer of Chimerix, Inc. since September 2, 2014 until April 7, 2020 and served as its Office of Chief Executive Officer from 2019 to 2019. Dr. Nichols joined the Chimerix, Inc. from ViiV Healthcare, where he was the Head of Global Development. Prior to his tenure at ViiV, Dr. Nichols spent ten years at GlaxoSmithKline (GSK plc) leading multiple global antiviral programs in the United States and Europe, including the development and regulatory submissions to the U.S. Food and Drug Administration (the FDA) and the European Medicines Agency for the approval of Tivicay and the recent FDA approval of Triumeq. Dr. Nichols spent four years on the faculty of the Fred Hutchinson Cancer Research Center in Seattle, WA, where he was the Principal investigator on NIH-funded grants exploring the prevention and treatment of CMV and respiratory virus infections in HCT recipients. Dr. Nichols received his M.D. from Duke University and earned an M.S. in Epidemiology from the University of Washington, where he completed a Fellowship in Infectious Diseases.

Positions